Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunome Inc IMNM

Healthcare Biotechnology
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its... see more

Recent & Breaking News (NDAQ:IMNM)

Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity

Business Wire May 23, 2023

Immunome Reports First Quarter 2023 Financial Results

Business Wire May 5, 2023

Immunome Reports Fourth Quarter and Full Year 2022 Financial Results

Business Wire March 16, 2023

Immunome to Present at 13th Annual World ADC London Conference

Business Wire March 9, 2023

Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Business Wire February 8, 2023

AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets

PR Newswire January 6, 2023

Immunome Reports Third Quarter 2022 Financial Results

Business Wire November 14, 2022

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Business Wire November 7, 2022

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Business Wire August 23, 2022

Immunome Reports Second Quarter 2022 Financial Results

Business Wire August 5, 2022

Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1

Business Wire July 6, 2022

Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Business Wire June 9, 2022

Immunome to Present at the Jefferies Healthcare Conference

Business Wire June 2, 2022

Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Business Wire May 23, 2022

Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Business Wire May 19, 2022

Immunome Reports First Quarter 2022 Financial Results

Business Wire May 12, 2022

Immunome Reports Fourth Quarter and Full Year 2021 Financial Results

Business Wire March 28, 2022

FDA Lifts Clinical Hold on Immunome's IMM-BCP-01 IND Application for the Treatment of COVID-19

Business Wire March 11, 2022

Immunome's Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing

Business Wire February 8, 2022

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Business Wire January 10, 2022